Regeneron Pharmaceuticals Inc
General ticker "REGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $80.9B
Regeneron Pharmaceuticals Inc follows the US Stock Market performance with the rate: 14.3%.
Estimated limits based on current volatility of 1.6%: low 694.78$, high 717.43$
Factors to consider:
- Company included in S&P500 list
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [654.49$, 982.37$]
- 2024-12-30 to 2025-12-30 estimated range: [654.09$, 997.58$]
Financial Metrics affecting the REGN estimates:
- Positive: Non-GAAP EPS, $ of 43.78 > 2.29
- Positive: Operating profit margin, % of 30.85 > 19.51
- Negative: Investing cash flow per share, $ of -29.85 <= -3.48
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.68 > 7.10
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term REGN quotes
Long-term REGN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $16,117.30MM | $12,262.80MM | $13,119.30MM |
| Operating Expenses | $7,170.50MM | $7,523.90MM | $9,072.20MM |
| Operating Income | $8,946.80MM | $4,738.90MM | $4,047.10MM |
| Non-Operating Income | $379.00MM | $119.90MM | $152.20MM |
| Interest Expense | $57.30MM | $59.40MM | $73.00MM |
| R&D Expense | $2,908.10MM | $3,592.50MM | $4,439.00MM |
| Income(Loss) | $9,325.80MM | $4,858.80MM | $4,199.30MM |
| Taxes | $1,250.50MM | $520.40MM | $245.70MM |
| Profit(Loss) | $8,075.30MM | $4,338.40MM | $3,953.60MM |
| Stockholders Equity | $18,768.80MM | $22,664.00MM | $25,973.10MM |
| Inventory | $1,951.30MM | $2,401.90MM | $2,580.50MM |
| Assets | $25,434.80MM | $29,214.50MM | $33,080.20MM |
| Operating Cash Flow | $7,081.30MM | $5,014.90MM | $4,594.00MM |
| Capital expenditure | $551.90MM | $590.10MM | $926.40MM |
| Investing Cash Flow | $-5,384.70MM | $-3,784.60MM | $-3,185.10MM |
| Financing Cash Flow | $-1,005.80MM | $-1,009.00MM | $-1,790.10MM |
| Earnings Per Share* | $76.40 | $40.51 | $37.05 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.